Toboroz
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600· Hoffmann-La Roche· Forrás
Toboroz
First in Human Study of SIM0610 in Solid Tumors
NCT07348211· 1. fázis· Jiangsu Simcere Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032· 3. fázis· Hutchmed· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Fut, nem toboroz
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660· 1/2. fázis· Acerand Therapeutics (Shanghai) Limited· Forrás
Toboroz
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· 2/3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
NCT05749887· Chongqing University Cancer Hospital· Forrás
Toboroz
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332· 3. fázis· Fudan University· Forrás
Fut, nem toboroz
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988· 3. fázis· Dizal Pharmaceuticals· Forrás
Toboroz
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
NCT05551208· 2. fázis· Chongqing University Cancer Hospital· Forrás
Fut, nem toboroz
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· 3. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Toboroz
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605· 1/2. fázis· BeOne Medicines· Forrás
Toboroz
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423· 2. fázis· Zenith Epigenetics· Forrás
Fut, nem toboroz
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· 3. fázis· Jiangsu HengRui Medicine Co., Ltd.· Forrás
Toboroz
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
NCT04555226· Chongqing University Cancer Hospital· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT04494503· 1/2. fázis· Ascentage Pharma Group Inc.· Forrás
Toboroz
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
NCT04409860· Chongqing University Cancer Hospital· Forrás
Toboroz
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
NCT04906434· 1. fázis· Abbisko Therapeutics Co, Ltd· Forrás
Fut, nem toboroz
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· 1/2. fázis· Dizal Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977· 3. fázis· BeiGene· Forrás
Fut, nem toboroz
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230· 3. fázis· BeiGene· Forrás
Fut, nem toboroz
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986· 3. fázis· AstraZeneca· Forrás